178 related articles for article (PubMed ID: 32171585)
1. Corrigendum to "Biochemical and biophysical characterization of curcumin binding to human mitotic kinesin Eg5: Insights into the inhibitory mechanism of curcumin on Eg5" [Int. J. Biol. Macromol. 109 (2018) 1189-1208].
Raghav D; Sebastian J; Rathinasamy K
Int J Biol Macromol; 2020 May; 150():1349-1350. PubMed ID: 32171585
[No Abstract] [Full Text] [Related]
2. Corrigendum to "Biochemical and Biophysical characterization of curcumin binding to human mitotic kinesin Eg5: Insights into the inhibitory mechanism of curcumin on Eg5" [Int. J. Biol. Macromol. 109 (2018) 1189-1208].
Raghav D; Sebastian J; Rathinasamy K
Int J Biol Macromol; 2020 Jan; 143():1033-1034. PubMed ID: 31864780
[No Abstract] [Full Text] [Related]
3. Biochemical and Biophysical characterization of curcumin binding to human mitotic kinesin Eg5: Insights into the inhibitory mechanism of curcumin on Eg5.
Raghav D; Sebastian J; Rathinasamy K
Int J Biol Macromol; 2018 Apr; 109():1189-1208. PubMed ID: 29162464
[TBL] [Abstract][Full Text] [Related]
4. Corrigendum to "Biocompatible, biodegradable and thermo-sensitive chitosan-g-poly(N-isopropylacrylamide) nanocarrier for curcumin drug delivery" [Int. J. Biol. Macromol. 49 (2011) 161-172].
Rejinold NS; Sreerekha PR; Chennazhi KP; Nair SV; Jayakumar R
Int J Biol Macromol; 2019 Aug; 135():1279-1282. PubMed ID: 31253371
[No Abstract] [Full Text] [Related]
5. Significant decrease of ADP release rate underlies the potent activity of dimethylenastron to inhibit mitotic kinesin Eg5 and cancer cell proliferation.
Sun L; Sun X; Xie S; Yu H; Zhong D
Biochem Biophys Res Commun; 2014 May; 447(3):465-70. PubMed ID: 24732354
[TBL] [Abstract][Full Text] [Related]
6. Corrigendum to "Investigating the site selective binding of busulfan to human serum albumin: Biophysical and molecular docking approaches" [Int. J. Biol. Macromol. 107 (2018) 1414-1421].
Siddiqi M; Nusrat S; Alam P; Malik S; Chaturvedi SK; Ajmal MR; Abdelhameed AS; Khan RH
Int J Biol Macromol; 2020 Aug; 157():774. PubMed ID: 32331792
[No Abstract] [Full Text] [Related]
7. Corrigendum to "Curcumin-laden dual-targeting fucoidan/chitosan nanocarriers for inhibiting brain inflammation via intranasal delivery" [Int. J. Biol. Macromol. 181 (2021) 835-846].
Don TM; Chang WJ; Jheng PR; Huang YC; Chuang EY
Int J Biol Macromol; 2022 May; 206():1040-1041. PubMed ID: 35369969
[No Abstract] [Full Text] [Related]
8. Corrigendum to "Improvement of pneumonia by curcumin-loaded bionanosystems based on platycodon grandiflorum polysaccharides via calming cytokine storme" [Int. J. Biol. Macromol. Volume 202, 31 March 2022, pages 691-706.
Li Y; Guo C; Chen Q; Su Y; Guo H; Liu R; Sun C; Chen D
Int J Biol Macromol; 2024 Jun; 270(Pt 2):132201. PubMed ID: 38761698
[No Abstract] [Full Text] [Related]
9. Morelloflavone as a novel inhibitor of mitotic kinesin Eg5.
Ogunwa TH; Taii K; Sadakane K; Kawata Y; Maruta S; Miyanishi T
J Biochem; 2019 Aug; 166(2):129-137. PubMed ID: 30785183
[TBL] [Abstract][Full Text] [Related]
10. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5.
DeBonis S; Simorre JP; Crevel I; Lebeau L; Skoufias DA; Blangy A; Ebel C; Gans P; Cross R; Hackney DD; Wade RH; Kozielski F
Biochemistry; 2003 Jan; 42(2):338-49. PubMed ID: 12525161
[TBL] [Abstract][Full Text] [Related]
11. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.
Brier S; Lemaire D; Debonis S; Forest E; Kozielski F
Biochemistry; 2004 Oct; 43(41):13072-82. PubMed ID: 15476401
[TBL] [Abstract][Full Text] [Related]
12. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents.
Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F
J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877
[TBL] [Abstract][Full Text] [Related]
13. Protein Phosphatase 2A (PP2A) Regulates EG5 to Control Mitotic Progression.
Liu Y; Zhang Z; Liang H; Zhao X; Liang L; Wang G; Yang J; Jin Y; McNutt MA; Yin Y
Sci Rep; 2017 May; 7(1):1630. PubMed ID: 28487562
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel scaffolds to inhibit human mitotic kinesin Eg5 targeting the second allosteric binding site using in silico methods.
Makala H; Ulaganathan V
J Recept Signal Transduct Res; 2018 Feb; 38(1):12-19. PubMed ID: 29041840
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines.
Tcherniuk S; van Lis R; Kozielski F; Skoufias DA
Biochem Pharmacol; 2010 Mar; 79(6):864-72. PubMed ID: 19896928
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum to "Deciphering the enhanced inhibitory, disaggregating and cytoprotective potential of promethazine towards amyloid fibrillation." [Int. J. Biol. Macromol. 106 (2018) 851-863].
Nusrat S; Zaman M; Masroor A; Siddqi MK; Zaidi N; Neelofar K; Abdelhameed AS; Khan RH
Int J Biol Macromol; 2020 Aug; 157():775-776. PubMed ID: 32331791
[No Abstract] [Full Text] [Related]
17. Corrigendum to "Synthesis, characterization and cytocompatibility studies of α-chitin hydrogel/nano hydroxyapatite composite scaffolds" [Int. J. Biol. Macromol. 49 (2011) 20-31].
Kumar PTS; Srinivasan S; Lakshmanan VK; Tamura H; Nair SV; Jayakumar R
Int J Biol Macromol; 2019 Oct; 138():1138-1141. PubMed ID: 31279592
[No Abstract] [Full Text] [Related]
18. Corrigendum to "Development and characterization of cuttlefish (Sepia officinalis) skin gelatin-protein isolate blend films" [Int. J. Biol. Macromol. 105 (2017) 1491-1500].
Kchaou H; Jridi M; Abdelhedi O; Benbettaïeb N; Karbowiak T; Nasri M; Debeaufort F
Int J Biol Macromol; 2018 Oct; 117():1374. PubMed ID: 29803291
[No Abstract] [Full Text] [Related]
19. Corrigendum to "Preparation and characterization of antibacterial, eco-friendly edible nanocomposite films containing Salvia macrosiphon and nanoclay" [Int. J. Biol. Macromol. 113(2018) 66-72].
Davachi SM; Shekarabi AS
Int J Biol Macromol; 2018 Aug; 115():1268. PubMed ID: 29789145
[No Abstract] [Full Text] [Related]
20. Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism.
Talapatra SK; Anthony NG; Mackay SP; Kozielski F
J Med Chem; 2013 Aug; 56(16):6317-29. PubMed ID: 23875972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
